CO3 Prediction of Long-Term Factor IX Durability Among Hemophilia B Patients Treated with Fidanacogene Elaparvovec Gene Therapy
Jun 1, 2024, 00:00 AM
10.1016/j.jval.2024.03.093
https://www.valueinhealthjournal.com/article/S1098-3015(24)00208-0/fulltext
Section Title :
Section Order :
10310
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00208-0&doi=10.1016/j.jval.2024.03.093